Plasma phosphorylated tau (p-tau231) and total tau (t-tau) as prognostic markers of neurological outcome after cardiac arrest - a multicentre study
Year: 2024
Type: article
Study design: Observational Study
Abstract: PURPOSE: We studied the promising Alzheimer biomarker plasma tau phosphorylated at threonine 231 (p-tau231) in a cohort of cardiac arrest patients who survived to intensive care to predict long-term neurological outcomes. We also compared it to total tau (t-tau), which has demonstrated predictive abilities of neurological outcome post-cardiac arrest. METHODS: This observational multicentre cohort study included 425 patients admitted to intensive care after cardiac arrest. Plasma p-tau231 was retrospectively analysed at admission, 12 and 48 h after cardiac arrest. The association of the Cerebral Performance Category (CPC) with p-tau231 was analysed with a one-way analysis of variance (ANOVA). CPC was modelled using multivariate ordinal logistic regression, and the biomarkers' prognostic performance was assessed by the area under the receiver operating characteristic curve (AUC). RESULTS: Increasing p-tau231 levels were significantly associated with worse CPC (p < 0.001). P-tau231 showed moderate prognostic abilities (AUC: 0.69 on admission, 0.72 at 12 h, and 0.71 at 48 h) for all patients but did not improve neurological prognostication after adjusting for clinical covariates. Elevated levels of t-tau were significantly associated with a worse outcome at all time points (p < 0.001). T-tau significantly improved neurological prognosis at 48 h after adjusting for covariates (AUC: 0.95, 95 % CI 0.93-0.98, p < 0.001) compared to the clinical covariate reference model (AUC: 0.88, 95 % CI 0.84-0.93). CONCLUSIONS: Although p-tau231 showed moderate neurological prognostic ability, t-tau was a stronger predictor, particularly at 48 h, even after adjusting for clinical covariates.
Source: Resuscitation
Language: English
Subfield: Emergency Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,160
Funders: Alzheimer's Association, Henry Luce Foundation, EU Joint Programme – Neurodegenerative Disease Research, European Commission, Crafoordska Stiftelsen, Hjärnfonden, Hjärt-Lungfonden, Vetenskapsrådet, Medicinska Forskningsrådet, Kirsten og Freddy Johansens Fond, Alzheimerfonden, Region Skåne, Skånes universitetssjukhus, Fondation pour la Recherche sur Alzheimer
Awards: G1135383168, G1222782219, G1311708188, G1395296334, The Alzheimer’s Association quality control (QC) program for CSF and plasma biomarkers - Continuation, G1834056249, Understanding Alzheimer Blood Biomarkers for Tau Pathology, G2385484910, G2493772985, G2501682398, G2634670634, The Alzheimer biomarker toolbox – use in pathogenic studies, diagnostics and theragnostics, G3027168043, G308275008, G313301595, G3501174345, G366952799, G4206382240, G4404751248, G4495868458, G4588880881, G5063629206, Tau pathology in Alzheimer´s - understanding pathophysiology through biomarkers in blood and CSF, G5592886007, G5619554209, G5783412400, G5867605609, G6125480915, G6142763750, G6168044258, G6772068474, G7143958211, G7404442218, G7748812462, G791739130, G92992353
OpenAlex ID: W4404959993
